NL-OMON37387撤回不适用
Pilot feasibility study of Ferinject® in patients with esophageal cancer - ARCHIE-1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Potentially operable and resectable patients with esophageal cancer
- •- Age 18 year and older
- •- Hb < 7.5 mmol/L in women and Hb < 8.1 mmol/L in men
- •- TSAT < 20%, Ferritine < 100 µg/L * absolute iron deficiency
- •- TSAT < 20%, Ferritine > 100 µg/L * functional iron deficiency
排除标准
- •- T4 carcinomas
- •- Inoperable due to comorbidity or ASA IV
- •- Irresectability
- •- Metastasis
- •- Erythropoiesis stimulating agents within 3 months before screening
- •- Ferritine > 500 µg/L
研究者
相似试验
进行中（未招募）
1 期
A pilot trial of intravenous iron for the treatment of low iron levels in adult patients with cystic fibrosis.Cystic fibrosisEUCTR2018-002366-39-GBniversity of Oxford / Clinical Trials and Research Governance20
尚未招募
不适用
Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative ChemotherapyNeoplasmsKCT0006908Asan Medical Center330
已完成
3 期
Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)Iron DeficiencyAnaemiaIron Deficiency AnemiaChronic Heart FailureNCT00520780Vifor Pharma456
进行中（未招募）
1 期
Treatment with daratumumab injections in moderate to severe ME/CFSMyalgic Encephalomyelitis/Chronic Fatigue SyndromeMedDRA version: 20.1Level: LLTClassification code 10028414Term: Myalgic encephalomyelitisSystem Organ Class: 100000004862EUCTR2022-000281-18-NOHaukeland University Hospital, Dept. of Oncology and Medical Physics10
进行中（未招募）
1 期
Daratumumab in ME/CFSMyalgic Encephalomyelitis/Chronic Fatigue SyndromeMedDRA version: 26.1Level: LLTClassification code: 10028414Term: Myalgic encephalomyelitis Class: 10021881CTIS2024-512500-19-00Helse Bergen HF10